Ep. 397 - What the U.S. midterms mean for biopharma
Ep. 397 - What the U.S. midterms mean for biopharma
Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data showing pelacars
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout of Unnatural Products. This episode of the BioCentury This Week podcast has been brought to you by Tigermed. View full story: https://www.biocentury.com/article/661519 #BiotechPolicy #FDA #DrugPricing #Cardiovascular #Immunotherapy 0:01 Sponsor Message: Tigermed 5:06 FDA Leadership After Midterms 12:41 HHS and Drug Pricing 17:34 Pelacarsen Readout at AHA 22:31 SITC Abstract Highlights 25:57 argenx’s Peptide Deal To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text